|
|
Below is a list of the reports in the category you have selected. Click to order the report or download a brochure.
Therapeutic Classes
Therapeutic Sub-Category:
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q2 2010 |  |
|
Focus Area:
| Osteoporosis |  |
|
Specialty/Panel Description:
| Endocrinologists, Internal Medicine, Rheumatologists / N. America, Europe, New Zealand |
|
|
Publication Date:
| 06/29/2010 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ210-48 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| This report captures discussions with four US, two European and one New Zealand osteoporosis thought leaders immediately following the news of Prolia’s approval by FDA and EMEA. Some specific questions the Panel addresses:
• Will physicians administer Prolia themselves, or refer patients to hospitals or clinics? How will the “Prolia Plus” program influence this decision?
• How will pricing in the U.S. and Europe impact reimbursement?
• What are Panelists’ perceptions of Prolia’s efficacy and safety vs. zoledronic acid and bisphosphonates, and how will this impact usage?
Other points of focus for this Panel include:
• Reactions to FDA’s recent warning on the long-term use of bisphosphonates,
• Cortical bone,
• Calcium mortality,
• Bisphosphonates,
• Cathepsin K inhibitors,
• Transdermal PTH,
• Sclerostin / DKK-1,
• SERMs,
• Oral calcitonin, and
• Calcilytics.
|
|
|
Brochures:
| Osteoporosis Brochure Q2 2010
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q1 2010 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists/N. America, Europe |
|
|
Publication Date:
| 04/01/2010 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ110-47 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| This report, the 47th in our Osteoporosis series, captures discussions with four US and two European osteoporosis thought leaders. The Panel spends a considerable amount of time discussing Amgen’s strategy for gaining approval and positioning for Prolia. They cover the issues relative to the REMS program, pricing, target market and competitive strengths and weaknesses.
Other points of focus for this Panel include: FDA’s recent warning on the long-term use of bisphosphonates; Anabolic properties of cathepsin K inhibitors; Transdermal PTH; generic knock-offs of teriparatide; Anti-sclerostin MAbs; SERMs; Oral calcitonin; Calcilytics (minor discussion); DEXA; and 3rd-world markets.
|
|
|
Brochures:
| Osteoporosis Brochure Q1 2010
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q4 2009 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists / Europe, N. America |
|
|
Publication Date:
| 12/29/2009 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ409-46 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| Osteoporosis Thought Leader Panel #46 is our year-end wrap-up of developments in the area of non-hematologic bone disease, based on interviews with six members of our internationally recognized panel. In this edition we share their perspective on the “big news”, e.g. the status of Prolia. We also discuss topics that have received less attention as of late, including Conbriza (bazedoxifene), Enteripep (oral calcitonin) and oral PTH. |
|
|
Brochures:
| Osteoporosis Brochure Q4 2009
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q3 2009 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Global Osteoporosis KOLs |
|
|
Publication Date:
| 10/15/2009 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ309-45 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| This report, the 45th in our osteoporosis series, provides our first opportunity to discuss the ASBMR 2009 with six members of our internationally recognized thought leader panel. Some of the topics they cover include:
- Osteonecrosis of the jaw associated with denosumab;
- Expected positioning of denosumab vs. zoledronic acid;
- Pricing and reimbursement;
- Histomorphometry;
- Other RANKL inhibitors;
- Sclerostin vs DKK1 approaches;
- Oral / IV bisphosphonates;
- Oral PTH;
- Cathepsin K; and
- Calcilytics.
|
|
|
Brochures:
| Osteoporosis Brochure Q3 2009
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q2 2009 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists, Internal Medicine/N. America, Europe |
|
|
Publication Date:
| 07/01/2009 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ209-44 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| In Osteoporosis Thought Leader Panel #44 we asked six internationally recognized osteoporosis thought leaders to tell us what was on their minds in the run-up to ASBMR 2009. In particular they are thinking about: The market dynamics that will be affected by the imminent introduction of Prolia (denosumab); New indications and cost pressures on Reclast/Aclasta; Advantages of alternative PTH formulations; The competition between PTH based and non-PTH based anabolics; Differentiating characteristics of cathepsin K inhibitors; Decoupling resorption and formation; Use of bone active agents in the prevention and treatment of cancer; Use of oncologic agents for the preservation or increase of bone mass, potentially outside the cancer setting; SERMs and SARMs.
|
|
|
Brochures:
| Osteoporosis Brochure Q2 2009
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q109 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists / U.S., Canada, Europe, New Zealand |
|
|
Publication Date:
| 04/13/2009 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ109-43 |
|
|
Pricing:
| $7,000.00 |
|
|
Abstract:
| To develop this analysis, the 43rd in our osteoporosis series, we conducted a thought exercise with United States (US; n=5) and Rest of World (ROW; n=6) rheumatologists and endocrinologists in March-April 2009. The purpose was to identify their “must have” branded and generic drugs for their real-world practice in the year 2015. |
|
|
Brochures:
| Osteoporosis Brochure Q1 2009
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q408 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists/N. America, Europe, New Zealand |
|
|
Publication Date:
| 12/03/2008 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ408-42 |
|
|
Pricing:
| $6,000.00 |
|
|
Abstract:
| For this report we conducted primary interviews with six global osteoporosis thought leaders (3 Americans, 2 Italians and 1 New Zealander). Some of the topics that the Panel addresses this quarter: -- Anabolics, antiresorptives and steroids for glucocorticoid induced osteoporosis;
-- Bisphosphonates and transverse femoral shaft fractures; -- Positioning denosumab vs. zoledronic acid; -- Is zoledronic acid’s mortality benefit real and unique; -- Does denosumab have a problem with rebound? Infection? Malignancy? Osteonecrosis of the jaw; -- Opportunities for next-generation RANKL antibodies; -- Opportunities for a cathepsin K inhibitor; -- What have we learned about how to run a fracture healing trial, and what drugs are most likely to be optimal for this indication?; -- What strategic approaches are next-generation PTH manufacturers using to try to differentiate their drugs from teriparatide?; -- Calcilytics, sclerostin, Dkk1; -- SERMs vs. SERMs + estrogen; -- PGE2; and more. |
|
|
Brochures:
| Osteoporosis Brochure Q4 2008
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q3 2008 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists, Internal Medicine / N. America, Europe |
|
|
Publication Date:
| 10/06/2008 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ308-41 |
|
|
Pricing:
| $6,000.00 |
|
|
Abstract:
| For this report, we spoke with seven North American (6) and European (1) osteoporosis thought leaders in September 2008 and asked them to expound upon the significance of the data that was presented at ASBMR. Some of the topics that the Panel addresses this quarter: 1) The Panel votes on choice of therapy if they could ONLY have denosumab or zoledronic acid available to them. This report shares the outcome of that vote, and the strengths, weaknesses and “wild cards” for each drug. 2) How can you get a placebo controlled trial past a Western IRB? 3) Anabolics vs. antiresorptives for glucocorticoid induced osteoporosis. 4) The value of vitamin D / Ca supplementation adjunctive to antiresorptive therapy. 5) The politics of the ASBMR, national and local osteoporosis societies (fiefdoms) and governmental regulatory bodies. 6) FRAX and DEXA, Fosamax, Actonel and Boniva, Cathepsin K inhibitors, lasofoxifene, bazedoxifene, BAZE + CEE, raloxifene and arzoxifene, Strontium, calcilytics, more. |
|
|
Brochures:
| Osteoporosis Brochure Q3 2008
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q2 2008 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Rheumatologists, Internal Medicine/N. America, Europe |
|
|
Publication Date:
| 06/30/2008 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ208-40 |
|
|
Pricing:
| $6,000.00 |
|
|
Abstract:
| Our Pre-ASBMR 2008 edition of our Osteoporosis Thought leader Panel is the 40th iteration of the series. We spoke with seven North American (4) and European (3) osteoporosis thought leaders in June 2008 and asked them to predict the results that we can expect to see released at the meeting. Some of the topics that the Panel chose to address include:
Amgen’s Ph-III results for denosumab;
Emerging data on zoledronic acid;
Ronacaleret development program;
Do turnover markers matter to a cathepsin K inhibitor?
Advantages for any of the new PTH molecules or dose forms;
Which is going to be a better anabolic: AMG-785, BHQ-880 or ronacaleret?
Which drugs will capitalize on the cortical bone mechanisms?
Which drugs are going to be most effective in the very elderly population?
Is rebound of bone markers a good thing or a bad thing?
What is the value of a breast cancer claim?
Why is everybody running bone healing trials?
What’s the deal with vitamin D?
|
|
|
Brochures:
| Osteoporosis Brochure Q2 2008
|
|
|
|
Document Title:
| Thought Leader Insight & Analysis -- Osteoporosis Q1 2008 | |
|
Focus Area:
| Osteoporosis | |
|
Specialty/Panel Description:
| Endocrinologists, Internal Medicine/N. America, Europe |
|
|
Publication Date:
| 02/29/2008 |
|
|
Principal Authors:
| Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA |
|
|
Product Code:
| MBOQ108-39 |
|
|
Pricing:
| $6,000.00 |
|
|
Abstract:
| Completing our 10th full year of ongoing discussions with our Osteoporosis Thought Leader Panel, this analysis was derived from seven interviews with North American (5) and European (2) osteoporosis thought leaders. These conversations took place November 2007 – February 2008.
We are experiencing a seismic event in the treatment of osteoporosis. The first question being asked of any new product now is “How is this better than alendronate?” Panelists provide insight into the cross currents of efficacy, safety, convenience and cost to help predict who will survive, and who will thrive in this maturing market. |
|
|
Brochures:
| Osteoporosis Brochure Q1 2008
|
|
|
|